Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.200
Buy
RSI(14)
65.222
Neutral
STOCH(KDJ)(9,3,3)
50.631
Sell
ATR(14)
0.407
High Vlolatility
CCI(14)
73.082
Neutral
Williams %R
46.008
Neutral
TRIX(12,20)
3.260
Buy
StochRSI(14)
1.925
Oversold
Search
Entera Bio Ltd
ENTXAdd to Watchlist
2.990USD
+0.040+1.36%
Close 07-31 16:00（ET）Quotes delayed by 15 min
139.40MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.36%
5 Days
+45.85%
1 Month
+76.92%
6 Months
+118.25%
Year to Date
+54.12%
1 Year
+53.33%
Key Figures
2.950Open
3.200High
1.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.27%Turnover Ratio
2.950Prev. Close
2.920Low
2.22MTurnover
LossP/E Static
13.04P/B
0.00%Div Yield TTM
-71.28%ROA
3.22052wk High
0.06Volume Ratio
-9.54MNet Profit
46.62MShares
-0.2619EPS TTM
1.54Beta
-82.33%ROE
0.91052wk Low
9.49%Amplitude
--Gross Margin
139.40MMarket Cap
12.49Reward/Risk
5.80%Risk Rate
TradingKey Stock Score of Entera Bio Ltd
Currency: USD Updated: 2026-07-31Key Insights
Entera Bio Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Entera Bio Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Entera Bio Ltd Highlights
StrengthsRisks
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.00K.
Undervalued
The company’s latest PE is -11.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.31M shares, decreasing 0.05% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 11.55K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.26.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
9.000
Target Price
+200.00%
Upside Space
Entera Bio Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
9.000
Target Price
+200.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Entera Bio Ltd
ENTX
1
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
3.224
Sell
MA10
2.628
Buy
MA20
2.186
Buy
MA50
1.676
Buy
MA100
1.440
Buy
MA200
1.705
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Entera Bio Ltd Info
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Ticker SymbolENTX
CompanyEntera Bio Ltd
CEOToledano (Miranda Jayne)
Websitehttps://enterabio.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Entera Bio Ltd (ENTX)?
The current price of Entera Bio Ltd (ENTX) is 2.99.
What is the symbol of Entera Bio Ltd?
The ticker symbol of Entera Bio Ltd is ENTX.
What is the 52-week high of Entera Bio Ltd?
The 52-week high of Entera Bio Ltd is 3.22.
What is the 52-week low of Entera Bio Ltd?
The 52-week low of Entera Bio Ltd is 0.91.
What is the market capitalization of Entera Bio Ltd?
The market capitalization of Entera Bio Ltd is 139.40M.
Is Entera Bio Ltd (ENTX) currently rated as Buy, Hold, or Sell?
According to analysts, Entera Bio Ltd (ENTX) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of Entera Bio Ltd (ENTX)?
The Earnings Per Share (EPS TTM) of Entera Bio Ltd (ENTX) is -0.25.